Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imatinib in LPS-induced Acute Lung Injury Model
NCT03328117Phase 1Completed
- Sponsor
- Exvastat Ltd
- Start
- Nov 2017
- Primary completion
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of imatinib in acute lung injury (ALI) (2 arms), sponsored by Exvastat Ltd. Primary endpoints: Change in the number of neutrophils in bronchoalveolar lavage fluid and Change in concentration of total protein in bronchoalveolar lavage fluid. Started Nov 2017; status: completed.
02
Drugs
03
Conditions
acute lung injury (ALI)
Beyond the preview
Go deeper on NCT03328117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03328117.